PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAflibercept
Eylea(aflibercept)
Ahzantive, Enzeevu, Eylea, Opuviz, Pavblu, Yesafili, Zaltrap (aflibercept) is a protein pharmaceutical. Aflibercept was first approved as Eylea on 2011-11-18. It is used to treat diabetic retinopathy and macular edema in the USA. It has been approved in Europe to treat colorectal neoplasms, degenerative myopia, diabetes complications, diabetic retinopathy, and macular edema amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
eye diseasesD005128
cardiovascular diseasesD002318
endocrine system diseasesD004700
Trade Name
FDA
EMA
Enzeevu, Eylea, Opuviz, Pavblu, Yesafili, Zaltrap
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Aflibercept
Tradename
Proper name
Company
Number
Date
Products
EyleaafliberceptRegeneron PharmaceuticalsN-125387 RX2011-11-18
2 products
Eylea HDafliberceptRegeneron PharmaceuticalsN-761355 RX2023-08-18
1 products
ZaltrapZiv-AfliberceptSanofiN-125418 RX2012-08-03
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
ahzantiveBiologic Licensing Application2025-03-26
eyleaBiologic Licensing Application2024-10-10
eylea hdBiologic Licensing Application2024-10-16
pavbluBiologic Licensing Application2025-03-04
zaltrapBiologic Licensing Application2023-12-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
macular edema—D008269—
diabetic retinopathyEFO_0003770D003930—
Agency Specific
FDA
EMA
Expiration
Code
aflibercept, Eylea, Regeneron Pharmaceuticals, Inc.
2030-02-08Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX44: Aflibercept
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01L: Ocular vascular disorder agents
— S01LA: Antineovascularisation agents
— S01LA05: Aflibercept
HCPCS
Code
Description
J0178
Injection, aflibercept, 1 mg
J9400
Injection, ziv-aflibercept, 1 mg
Clinical
Clinical Trials
560 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Macular degenerationD008268EFO_0001365H35.30——1——1
Vascular diseasesD014652EFO_0004264I77——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179———1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAflibercept
INNaflibercept
Description
Aflibercept, sold under the brandname Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and Europe.
Classification
Protein
Drug classreceptor molecules or membrane ligands, natural, modified or modified: vascular endothelial growth factor (VEGF) receptors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1742982
ChEBI ID—
PubChem CID—
DrugBankDB08885
UNII ID15C2VL427D (ChemIDplus, GSRS)
Target
Agency Approved
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
VEGF
NCBI Gene ID
7422
Protein name
vascular endothelial growth factor A, long form
Protein synonyms
vascular endothelial growth factor A121, vascular endothelial growth factor A165, Vascular permeability factor, VPF
Uniprot ID
P15692
Mouse ortholog
Vegfa (22339)
vascular endothelial growth factor A, long form (Q6WZL9)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eylea – Regeneron Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Zaltrap – Regeneron Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 12,038 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
28,737 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use